Nolvadex
(tamoxifen citrate)Phase 3Small molecule
Tamoxifen is used to treat breast cancer in women and men by blocking estrogen, which can help slow or stop cancer growth. It's also used to reduce the risk of breast cancer in high-risk women.[1] Nolvadex is currently being investigated across 4 indications[3], with its most advanced program in Phase 3.[1]
Nolvadex is one of 42 small molecule programs targeting Breast Ductal Carcinoma in Situ. It is currently in Phase 3.
4
Indications
108
Total Trials
7
Active Trials
41
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Nolvadex
SSan Diego Pacific Oncology & Hematology Associates
Phase 3
Adenocard
AstellasPreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
Ablavar
LLantheus Medical Imaging
Preclinical
Naltrexone/bupropion
Novo NordiskPreclinical
Sertraline ODT
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Liposomal Irinotecan and Apatinib
SSecond Affiliated Hospital, School of Medicine, Zhejiang University
Preclinical
Ibrance
PfizerPreclinical
Maxigesic
YYonsei University
Preclinical
Fluorothymidine F-18
MM.D. Anderson Cancer Center
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Breast Cancer77 trials
Show 74 more trials
Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes
Completed·—·Phase 2·NCT00007904·16 enrolled
Lapatinib and Tamoxifen in Treating Patients With Advanced or Metastatic Breast Cancer
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 1·NCT00424164·20 enrolled
Tamoxifen Citrate in Patients With Breast Cancer
Unknown status·—·Phase 3·NCT00963209·140 enrolled
Chemotherapy Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer
Completed·—·Phase 2·NCT00003953·39 enrolled
Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer
Completed·—·Phase 2·NCT00003042·41 enrolled
Gefitinib With or Without Tamoxifen in Treating Patients With Tamoxifen-Resistant Metastatic Breast Cancer
Completed·—·Phase 2·NCT00080743·2 enrolled
Exemestane Compared With Tamoxifen in Treating Women With Locally Recurrent or Metastatic Breast Cancer
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00002777·342 enrolled
Ductal Carcinoma in Situ6 trials
Fulvestrant or Tamoxifen in Treating Postmenopausal Women Who Are Undergoing Surgery for Ductal Carcinoma in Situ of the Breast
Unknown status·—·N/A·NCT00126464·100 enrolled
Show 3 more trials
Endometrial Cancer2 trials
Fallopian Tube Cancer2 trials
Spinal Cord Tumor1 trial
Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors
Completed·—·Phase 2·NCT00541138·50 enrolled
20 more indications
Progesterone Receptor Positive1 trial
Melanoma1 trial
Glioma1 trial
Treatment1 trial
Tamoxifen in Treatment of Acute Mania
Completed·—·Phase 3·NCT00411203·66 enrolled
Bladder Tumor1 trial
Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors
Completed·—·Phase 2·NCT02197897·15 enrolled
Patients With Solid Tumors1 trial
Ocular Melanoma1 trial
Malignant Glioma1 trial
Breast Carcinoma in Situ1 trial
Ovarian Cancer1 trial
Glioblastoma Multiforme1 trial
Breast Adenocarcinoma1 trial
Invasive Breast Carcinoma1 trial
Breast Ductal Carcinoma in Situ1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for tamoxifen citrate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details